Work

Rare occurrence: Colitis induced by nab-paclitaxel in metastatic pancreatic cancer treatment - A case report

Year: 2024

Type: article

Abstract: Nab-Paclitaxel is a standard first-line treatment for metastatic pancreatic adenocarcinoma. While this therapy has shown promise, it can lead to rare but severe adverse effects, including colitis. We report a case of a 63-year-old patient with metastatic pancreatic adenocarcinoma treated with nab-paclitaxel who developed severe colitis after the first cycle. symptoms included abdominal pain, vomiting, diarrhoea, and melena. Laboratory, biopsy, and sigmoidoscopy reports were suggestive of drug-induced colitis. Treatment involved antibiotics, anti-inflammatory drugs, and supportive care.This case underscores the importance of monitoring patients for colitis during nab-paclitaxel-based chemotherapy and considering treatment modification if necessary. Early intervention is critical in managing this rare but potentially serious complication.

Source: Panacea Journal of Medical Sciences

DOI: 10.18231/j.pjms.2024.159

Authors: Vishal Kulkarni, Madhusoodan M Gonenavar, Sandeep Kumbar, Sudhanshu Shukla, Tejashree Sridhar

Institutions: Healthcare Global Enterprises, KLE Academy of Higher Education and Research

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $48